Skip to Content
 

News: Home Page Research

Park named to VICC breast cancer leadership position

Thursday, May 17th, 2018

Ben Ho Park, MD, PhD, has been named co-leader of the Breast Cancer Research Program, director of Precision Oncology and associate director for Translational Research at Vanderbilt-Ingram Cancer Center. He will assume his new post Sept. 1.

Grant bolsters kidney cancer immunotherapy research

Friday, May 11th, 2018

Kimryn Rathmell, MD, PhD, Cornelius Abernathy Craig Professor of Medicine and director of the Division of Hematology and Oncology at Vanderbilt-Ingram Cancer Center (VICC), has received a grant to research the role of immunosuppression in the tumor microenvironment for kidney cancer.

Looking beyond the ‘magic bullet’ approach to drug discovery

Thursday, May 3rd, 2018

Vanderbilt researchers have developed a new process that can rapidly and inexpensively identify personalized cancer drugs derived from nature.

VICC annual scientific retreat set for May 3

Thursday, April 19th, 2018

The annual Vanderbilt-Ingram Cancer Center Scientific Retreat will be held Thursday, May 3, 8 a.m. to 3 p.m. at the Vanderbilt Student Life Center. The potential link between the body’s microbiome and cancer is the topic of this year’s event.

“Idling” cancer cells may return

Friday, April 13th, 2018

Vito Quaranta, MD, and colleagues have found that treated melanoma cells enter a previously unrecognized “idling” state. These idling cells may be primed to acquire resistance mutations and may constitute the bulk of residual disease.

Study finds broken circadian clock in human tumors

Thursday, March 29th, 2018

Human tumors appear to have a broken circadian clock, researchers at Vanderbilt University Medical Center report in the journal PeerJ.

Study tracks protein’s role in stem cell function

Thursday, March 22nd, 2018

Many types of cancer cells escape the body’s effort to kill them by overexpressing MCL-1, a protein important for blocking apoptosis, or programmed cell death. A recent study by Vivian Gama, PhD and colleagues indicates that MCL-1 also helps maintain the identity and ability of stem cells to differentiate, or give rise to other kinds of cells. 

Cancer immunotherapy drugs linked with more serious heart effects

Monday, March 12th, 2018

Vanderbilt University Medical Center investigators have identified a growing number of serious and sometimes fatal cases of heart problems among cancer patients treated with some forms of immunotherapy.

A new target for neuroblastoma

Friday, February 16th, 2018

A new study by Dai Chung, MD, and colleagues reports that a protein, called SIRT6, plays an important role in the growth of neuroblastoma and suggests that SIRT6 may be a target for new therapeutics for the disease.

Study seeks to boost breast tumor immune response

Thursday, February 8th, 2018

Targeting specific molecules in breast tumors, called methylating agents, can turn up the immune response, potentially making tumors responsive to immunotherapy, suggests a new study published in Nature Communications.

Next Page »